Angela Fragano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Angela Fragano has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Sophia Z. Shalhout
Department of Otolaryngology-Head and Neck Surgery, Division of Surgical Oncology, Mike Toth Cancer Research Center, Massachusetts Eye and Ear, Mass General Brigham, Boston, USA
3 shared publications - Pegah Ahadian
Kent State University
2 shared publications - Qiang Guan
Kent State University
2 shared publications - Tianyuan Guan
College of Public Health, Kent State University, Kent, OH 44242, USA
2 shared publications Gabriella Chefitz
Dermatology Branch, National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, Maryland, USA
1 shared publication- Isaac Brownell
Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by Springer Nature in Scientific Reports
Development and validation of machine learning-based prediction of depression progression using EHR data: a multi-institutional retrospective cohort study
Depression is common and often difficult to monitor for clinical worsening in real-world settings where structured symptom scales are inconsistently captured. Electronic health records allow large cohort analyses. Diagnostic-code based definitions offer a practical way to identify patients at risk for progression. We used a multi-institutional dataset (MedStar Health) to study adults with mild depression and evaluated whether machine learning models could predict progression to moderate or severe depression within two years. The cohort included 803 individuals with two years of continuous follow-up. A broad set of demographics, clinical, laboratory, socioeconomic, and healthcare utilization features was available. Models included logistic regression, random forest, gradient boosted trees, and a deep neural network (DNN). Gradient boosted trees showed balanced performance, defined as a trade-off between sensitivity and specificity with a modest improvement over baseline prevalence, while logistic regression demonstrated the strongest overall discrimination and generalization. The DNN showed lower accuracy than null classifier. These findings demonstrate that real-world EHR data can support risk prediction of depression worsening with stable and clinically relevant performance. These models may support earlier identification of patients who warrant closer monitoring or targeted follow-up.
- 24 September 2026
- Published by Springer Nature in Scientific Reports
Open AccessDevelopment and validation of machine learning-based prediction of depression progression using EHR data: a multi-institutional retrospective cohort study
Depression is common and often difficult to monitor for clinical worsening in real-world settings where structured symptom scales are inconsistently captured. Electronic health records allow large cohort analyses. Diagnostic-code based definitions offer a practical way to identify patients at risk for progression. We used a multi-institutional dataset (MedStar Health) to study adults with mild depression and evaluated whether machine learning models could predict progression to moderate or severe depression within two years. The cohort included 803 individuals with two years of continuous follow-up. A broad set of demographics, clinical, laboratory, socioeconomic, and healthcare utilization features was available. Models included logistic regression, random forest, gradient boosted trees, and a deep neural network (DNN). Gradient boosted trees showed balanced performance, defined as a trade-off between sensitivity and specificity with a modest improvement over baseline prevalence, while logistic regression demonstrated the strongest overall discrimination and generalization. The DNN showed lower accuracy than null classifier. These findings demonstrate that real-world EHR data can support risk prediction of depression worsening with stable and clinically relevant performance. These models may support earlier identification of patients who warrant closer monitoring or targeted follow-up.
- Open Access
Immunotherapy Significantly Improves Merkel Cell Carcinoma-Specific Survival: A Single-Cohort Propensity Score-Matched Analysis
Background: Immune checkpoint inhibitors (ICI) have improved outcomes in Merkel cell carcinoma (MCC). Population analyses suggest improved survival following the 2017 approval of ICI, but registry data lack treatment-level information including type of systemic therapy and initiation timepoint to directly estimate the benefit attributable to immunotherapy. This study compared Merkel Cell Carcinoma-specific survival between patients treated with first-line ICI versus cytotoxic chemotherapy. Methods: Patients were identified from the Seattle Merkel Cell Carcinoma Registry. Among 1,517 patients with MCC, 463 received first-line systemic therapy with either ICI or chemotherapy. Propensity scores were estimated using logistic regression including AJCC 8th stage, age, sex, MCPyV status, and immunosuppression. One-to-one nearest-neighbor matching produced balanced cohorts of 133 ICI-treated and 133 chemotherapy-treated patients. Merkel Cell Carcinoma-specific survival from therapy initiation was analyzed using Kaplan-Meier and Cox proportional hazards models with follow-up administratively censored at five years. Results: Baseline clinical characteristics were comparable between matched cohorts. ICI therapy was associated with significantly improved Merkel Cell Carcinoma-specific survival compared with chemotherapy (log-rank p<0.0001). Five-year Merkel Cell Carcinoma-specific survival was 56.8% (95% CI 46.8-65.6) for ICI versus 23.9% (95% CI 16.9-31.6) for chemotherapy. In multivariable stage-stratified Cox analysis, ICI remained independently associated with improved Merkel Cell Carcinoma-specific survival (HR 0.32, 95% CI 0.21-0.50; p<0.0001), while immunosuppression was associated with worse Merkel Cell Carcinoma-specific survival (HR 2.03, 95% CI 1.10-3.74; p=0.0228). Conclusions: ICI therapy was associated with substantially improved MCC-specific survival compared with chemotherapy.
Open AccessImmunotherapy Significantly Improves Merkel Cell Carcinoma-Specific Survival: A Single-Cohort Propensity Score-Matched Analysis
Background: Immune checkpoint inhibitors (ICI) have improved outcomes in Merkel cell carcinoma (MCC). Population analyses suggest improved survival following the 2017 approval of ICI, but registry data lack treatment-level information including type of systemic therapy and initiation timepoint to directly estimate the benefit attributable to immunotherapy. This study compared Merkel Cell Carcinoma-specific survival between patients treated with first-line ICI versus cytotoxic chemotherapy. Methods: Patients were identified from the Seattle Merkel Cell Carcinoma Registry. Among 1,517 patients with MCC, 463 received first-line systemic therapy with either ICI or chemotherapy. Propensity scores were estimated using logistic regression including AJCC 8th stage, age, sex, MCPyV status, and immunosuppression. One-to-one nearest-neighbor matching produced balanced cohorts of 133 ICI-treated and 133 chemotherapy-treated patients. Merkel Cell Carcinoma-specific survival from therapy initiation was analyzed using Kaplan-Meier and Cox proportional hazards models with follow-up administratively censored at five years. Results: Baseline clinical characteristics were comparable between matched cohorts. ICI therapy was associated with significantly improved Merkel Cell Carcinoma-specific survival compared with chemotherapy (log-rank p<0.0001). Five-year Merkel Cell Carcinoma-specific survival was 56.8% (95% CI 46.8-65.6) for ICI versus 23.9% (95% CI 16.9-31.6) for chemotherapy. In multivariable stage-stratified Cox analysis, ICI remained independently associated with improved Merkel Cell Carcinoma-specific survival (HR 0.32, 95% CI 0.21-0.50; p<0.0001), while immunosuppression was associated with worse Merkel Cell Carcinoma-specific survival (HR 2.03, 95% CI 1.10-3.74; p=0.0228). Conclusions: ICI therapy was associated with substantially improved MCC-specific survival compared with chemotherapy.
- Open Access
Development and Validation of Machine Learning-Based Prediction of Depression Progression Using EHR Data: A Multi-Institutional Retrospective Cohort Study
Background: Depression is a leading cause of global disability. Timely identification of patients at risk for clinical worsening remains a major challenge. Electronic health records (EHRs) facilitate large-scale, real-world analyses of disease trajectories. However, standardized symptom scale data such as the Patient Health Questionnaire-9 are often unavailable or recorded only as unstructured text. In this context, International Classification of Diseases (ICD10) diagnostic-code based severity progression provides a pragmatic alternative for developing predictive tools to identify worsening depression. Objective: We aim to develop and evaluate machine-learning and deep-learning models for predicting ICD10-defined progression from mild to moderate/severe depression using EHR data curated by the MedStar Health Research Institute (MHRI). Methods: We conducted a multi-institutional retrospective cohort analysis using the MHRI EHR database, which integrates data from 10 hospitals and 300 outpatient sites across the mid-Atlantic. Adults (≥18 years) with an initial ICD10 diagnosis of mild depression between 2017 and 2023 were included (N=2131). Nonprogressors were defined as patients whose mild major depressive disorder remained mild for 24 months (N=270). Progressors were defined as patients who developed moderate or severe ICD10 depression within 24 months of the index diagnosis (N=533). Data were stratified and split into (60%) training, (20%) validation, and (20%) test subsets. A heterogeneous feature set spanning demographics, healthcare utilization, socioeconomic indices, diagnostic context, and laboratory measurements were available. Logistic regression utilized elastic net regularization with fivefold cross validation, and random forest hyperparameters were tuned by grid search. XGBoost, CatBoost, and a deep neural network (DNN) were trained with standard learning rate, depth, class weighting, and early stopping. A deterministic top model selection framework applied prespecified thresholds of sensitivity at least 0.70 and AUC at least 0.70, and composite rankings integrated accuracy, sensitivity, specificity, and the overfitting gap. Results: The analytic cohort included 803 patients with complete two-year follow-up. Under the selection criteria, the DNN failed to meet the AUC threshold (0.671) and was excluded. Among the remaining models, XGBoost achieved the top composite score (accuracy = 0.72; AUC = 0.776; sensitivity = 0.77; specificity = 0.63; overfit gap = 0.112). Logistic regression ranked second (accuracy = 0.71; AUC = 0.797; sensitivity = 0.79; specificity = 0.61; overfit gap = 0.052), followed by CatBoost and random forest, the latter penalized for overfitting (gap = 0.278). The TinyLlama audit note, generated through a local Hugging Face pipeline, confirmed XGBoost as the most balanced model. Conclusions: Using EHR data from a multi-institutional regional health system, we developed and validated machine-learning models that predicted progression of depression. XGBoost demonstrated the most reliable composite performance. These findings support the feasibility of leveraging socioeconomic and EHR data to predict worsening depression and emphasize the importance of transparent model-selection frameworks for trustworthy clinical artificial intelligence.
Open AccessDevelopment and Validation of Machine Learning-Based Prediction of Depression Progression Using EHR Data: A Multi-Institutional Retrospective Cohort Study
Background: Depression is a leading cause of global disability. Timely identification of patients at risk for clinical worsening remains a major challenge. Electronic health records (EHRs) facilitate large-scale, real-world analyses of disease trajectories. However, standardized symptom scale data such as the Patient Health Questionnaire-9 are often unavailable or recorded only as unstructured text. In this context, International Classification of Diseases (ICD10) diagnostic-code based severity progression provides a pragmatic alternative for developing predictive tools to identify worsening depression. Objective: We aim to develop and evaluate machine-learning and deep-learning models for predicting ICD10-defined progression from mild to moderate/severe depression using EHR data curated by the MedStar Health Research Institute (MHRI). Methods: We conducted a multi-institutional retrospective cohort analysis using the MHRI EHR database, which integrates data from 10 hospitals and 300 outpatient sites across the mid-Atlantic. Adults (≥18 years) with an initial ICD10 diagnosis of mild depression between 2017 and 2023 were included (N=2131). Nonprogressors were defined as patients whose mild major depressive disorder remained mild for 24 months (N=270). Progressors were defined as patients who developed moderate or severe ICD10 depression within 24 months of the index diagnosis (N=533). Data were stratified and split into (60%) training, (20%) validation, and (20%) test subsets. A heterogeneous feature set spanning demographics, healthcare utilization, socioeconomic indices, diagnostic context, and laboratory measurements were available. Logistic regression utilized elastic net regularization with fivefold cross validation, and random forest hyperparameters were tuned by grid search. XGBoost, CatBoost, and a deep neural network (DNN) were trained with standard learning rate, depth, class weighting, and early stopping. A deterministic top model selection framework applied prespecified thresholds of sensitivity at least 0.70 and AUC at least 0.70, and composite rankings integrated accuracy, sensitivity, specificity, and the overfitting gap. Results: The analytic cohort included 803 patients with complete two-year follow-up. Under the selection criteria, the DNN failed to meet the AUC threshold (0.671) and was excluded. Among the remaining models, XGBoost achieved the top composite score (accuracy = 0.72; AUC = 0.776; sensitivity = 0.77; specificity = 0.63; overfit gap = 0.112). Logistic regression ranked second (accuracy = 0.71; AUC = 0.797; sensitivity = 0.79; specificity = 0.61; overfit gap = 0.052), followed by CatBoost and random forest, the latter penalized for overfitting (gap = 0.278). The TinyLlama audit note, generated through a local Hugging Face pipeline, confirmed XGBoost as the most balanced model. Conclusions: Using EHR data from a multi-institutional regional health system, we developed and validated machine-learning models that predicted progression of depression. XGBoost demonstrated the most reliable composite performance. These findings support the feasibility of leveraging socioeconomic and EHR data to predict worsening depression and emphasize the importance of transparent model-selection frameworks for trustworthy clinical artificial intelligence.